Dailypharm Live Search Close

What's patient-centered safety in the biopharmaceutical era?

By Lee, Hye-Kyung | translator Choi HeeYoung

22.09.07 06:18:12

°¡³ª´Ù¶ó 0
From the controversy over safety and accessibility to efforts to develop cutting-edge drugs in Korea,

The Ministry of Food and Drug Safety's GBC, policy discussion, Yoon's approval and salary are expected to proceed simultaneously

Along with the application of the world's first CAR-T cell therapy Kymriah and Zolgensma, an alternative treatment for spinal proximal phagocytosis (SMA), the biopharmaceutical era has opened in Korea. Controversy over safety and accessibility has not yet been resolved in the process of innovative biopharmaceuticals being developed and used to treat patients. Seo Kyung-won, director of NIFDS, who attended the debate, said, "It seems to be the first session related to patient safety during the 8th session of the GBC," adding, "Thinking about how and at what point patients' opinions should be contained should begin from now on." Director Seo said, "Although it was not actually implemented due to the spread of COVID-19, we

Lee, Hye-Kyung(hgrace7@dailypharm.com)
If you want to see the full article, please JOIN US (click)